SCHEMBL948679

SCHEMBL948679

CCOC(=O)c1ccc(OCC(C)C)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
ESR1 P03372 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
ESR2 Q92731 1/20 0.56
CA14 Q9ULX7 1/20 0.56
MAPT P10636 3/20 0.56
ALDH1A1 P00352 3/20 0.55
HPGD P15428 2/20 0.55
KDM4E B2RXH2 1/20 0.55
GAA P10253 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LMNA P02545 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
MAOA P21397 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27929357 0.90 KMT2A (0.60) KMT2AMAPTALDH1A1HPGDKDM4E
SCHEMBL7989426 0.89 MAPT (0.58) KMT2ACA12CA1CA2ESR1
SCHEMBL25936562 0.87 MAPT (0.53) KMT2ACA12CA1CA2ESR1
SCHEMBL27536527 0.87 MAPT (0.60) KMT2ACA12CA1CA2ESR1
SCHEMBL948187 0.87 GAA (0.62) KMT2AMAPTALDH1A1HPGDGAA
SCHEMBL5167985 0.86 CA12 (0.63) KMT2ACA12CA1CA2ESR1
SCHEMBL11339159 0.86 MAPT (0.55) KMT2ACA12CA1CA2ESR1
SCHEMBL24214161 0.85 MAPT (0.54) KMT2ACA12CA1CA2ESR1
SCHEMBL11347526 0.84 GAA (0.53) KMT2ACA12CA1CA2ESR1
SCHEMBL76052 0.84 ALDH1A1 (0.66) CA12CA1CA2ESR1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111825601-A Method for continuously preparing pimavanserin by using microchannel reactor 杭州珠联医药科技有限公司 2020-10-27 CN claimed
EP-2958950-B1 AN IMPROVED MAGNESIUM DICHLORIDE SUPPORTED TITANIUM CATALYST COMPOSITION FOR POLYOLEFIN POLYMERIZATION RELIANCE INDUSTRIES LTD (IN) 2019-09-11 EP claimed
US-20160002372-A1 Magnesium Dichloride Supported Titanium Catalyst Composition for Polyolefin Polymerization RELIANCE INDUSTRIES LIMITED (IN) 2016-01-07 US claimed
EP-2958950-A2 AN IMPROVED MAGNESIUM DICHLORIDE SUPPORTED TITANIUM CATALYST COMPOSITION FOR POLYOLEFIN POLYMERIZATION Reliance Industries Limited (IN) 2015-12-30 EP claimed
WO-2014128715-A2 AN IMPROVED MAGNESIUM DICHLORIDE SUPPORTED TITANIUM CATALYST COMPOSITION FOR POLYOLEFIN POLYMERIZATION RELIANCE INDUSTRIES LIMITED (IN) 2014-08-28 WO claimed
US-11440884-B2 Compounds, salts thereof and methods for treatment of diseases ACADIA PHARMACEUTICALS INC. (US) 2022-09-13 US disclosed
US-20210122713-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2021-04-29 US disclosed
CN-111825601-A Method for continuously preparing pimavanserin by using microchannel reactor 杭州珠联医药科技有限公司 2020-10-27 CN disclosed
EP-3672960-A2 COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES Acadia Pharmaceuticals Inc. (US) 2020-07-01 EP disclosed
EP-2958950-B1 AN IMPROVED MAGNESIUM DICHLORIDE SUPPORTED TITANIUM CATALYST COMPOSITION FOR POLYOLEFIN POLYMERIZATION RELIANCE INDUSTRIES LTD (IN) 2019-09-11 EP disclosed
WO-2019040104-A2 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2019-02-28 WO disclosed
US-20160002372-A1 Magnesium Dichloride Supported Titanium Catalyst Composition for Polyolefin Polymerization RELIANCE INDUSTRIES LIMITED (IN) 2016-01-07 US disclosed
EP-2958950-A2 AN IMPROVED MAGNESIUM DICHLORIDE SUPPORTED TITANIUM CATALYST COMPOSITION FOR POLYOLEFIN POLYMERIZATION Reliance Industries Limited (IN) 2015-12-30 EP disclosed
WO-2014128715-A2 AN IMPROVED MAGNESIUM DICHLORIDE SUPPORTED TITANIUM CATALYST COMPOSITION FOR POLYOLEFIN POLYMERIZATION RELIANCE INDUSTRIES LIMITED (IN) 2014-08-28 WO disclosed
EP-2257576-B1 A PROCESS FOR THE SYNTHESIS OF ALPHA-OLEFIN POLYMERIZATION PROCATALYSTS RELIANCE IND LTD (IN) 2013-02-20 EP disclosed
US-8283424-B2 Process for the synthesis of alpha-olefin polymerization procatalysts RELIANCE INDUSTRIES LIMITED (IN) 2012-10-09 US disclosed
US-20110015355-A1 PROCESS FOR THE SYNTHESIS OF ALPHA-OLEFIN POLYMERIZATION PROCATALYSTS RELIANCE INDUSTRIES LIMITED (IN) 2011-01-20 US disclosed
EP-2257576-A2 A PROCESS FOR THE SYNTHESIS OF ALPHA-OLEFIN POLYMERIZATION PROCATALYSTS Reliance Industries Limited (IN) 2010-12-08 EP disclosed
WO-2009116057-A2 A PROCESS FOR THE SYNTHESIS OF ALPHA-OLEFIN POLYMERIZATION PROCATALYSTS RELIANCE INDUSTRIES LIMITED (IN) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11440884-B2 Compounds, salts thereof and methods for treatment of diseases SLC10A1, VHL, CYP11B2 KMT2A 3216/4885CA12 233/4885CA1 872/4885
US-20210122713-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES SLC10A1, VHL, CYP11B2 KMT2A 3216/4885CA12 233/4885CA1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.